COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,843 Articles (22,553 medRxiv, 8,290 bioRxiv)

Most recent first Previous |  Page 1207: Articles 12061-12070  | Next

Place, cause and expectedness of death and relationship to the deceased are associated with poorer experiences of end-of-life care and challenges in early bereavement: Risk factors from an online survey of people bereaved during the COVID-19 pandemic
Selman, L. E., Farnell, D. J., Longo, M., Goss, S., Seddon, K., Torrens-Burton, A., Mayland, C. R., Wakefield, D., Johnston, B., Byrne, A., Harrop, E. J.
10.1101/2021.09.09.21263341 — Posted: 2021-09-14
CHARACTERIZING AND MANAGING AN EPIDEMIC: A FIRST PRINCIPLES MODEL AND A CLOSED FORM SOLUTION TO THE KERMACK AND MCKENDRICK EQUATIONS
Duclos, T. G., Reichert, T. A.
10.1101/2021.09.09.21263355 — Posted: 2021-09-14
Antibody responses to BNT162b2 mRNA vaccine: infection-naive individuals with abdominal obesity warrant attention
MALAVAZOS, A. E., Basilico, S., Iacobellis, G., Milani, V., Cardani, R., Boniardi, F., Dubini, C., Prandoni, I., Capitanio, G., Renna, L. V., Boveri, S., Carrara, M., Spuria, G., Cuppone, M. T., D'Acquisto, A., Carpinelli, L., Sacchi, M., Morricone, L., Secchi, F., Costa, E., Menicanti, L., Nisoli, E., Carruba, M. O., Ambrogi, F., Corsi Romanelli, M. M.
10.1101/2021.09.10.21262710 — Posted: 2021-09-14 Discussion: Onsite
SARS-COV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection
Richardson, J. R., Goetz, R., Mayr, V., Lohse, M. J., Holthoff, H.-P., Ungerer, M.
10.1101/2021.09.07.21262725 — Posted: 2021-09-14 Discussion: Onsite
Analytical performances of the COVISTIX and Panbio antigen rapid tests for SARS-CoV-2 detection in an unselected population (all commers)
Garcia-Cardenas, F., Franco, A., Cortes, R., Bertin, J., Valdez, R., Penaloza, F., Frias-Jimenez, E., Cedro-Tanda, A., Mendoza-Vargas, A., Reyes-Grajeda, J. P., Hidalgo-Miranda, A., Herrera, L. A.
10.1101/2021.09.10.21263410 — Posted: 2021-09-14
SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency
Takahashi, S., Peluso, M. J., Hakim, J., Turcios, K., Janson, O., Routledge, I., Busch, M. P., Hoh, R., Tai, V., Kelly, J. D., Martin, J. N., Deeks, S. G., Henrich, T. J., Greenhouse, B., Rodriguez-Barraquer, I.
10.1101/2021.09.09.21263139 — Posted: 2021-09-14 Discussion: Onsite
Iron related biomarkers predict disease severity in a cohort of Portuguese adult patients during COVID-19 acute infection
Moreira, A. C., Teles, M. J., Silva, T., Bento, C. M., Alves, I. S., Pereira, L. C., Guimaraes, J. T., Porto, G., Oliveira, P., Gomes, S.
10.1101/2021.09.09.21263251 — Posted: 2021-09-14
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization using a versatile adenovirus-inspired multimerization platform
Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C. J., Buisson, M., Gallet, S., Fenel, D., Vassal-Stermann, E., Schoehn, G., Poignard, P., Dagher, M.-C., Fender, P.
10.1101/2021.09.13.460076 — Posted: 2021-09-13
The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression
Bujanic, L., Shevchuk, O., von Kuegelgen, N., Ludwik, K., Koppstein, D., Zerna, N., Sickmann, A., Chekulaeva, M.
10.1101/2021.09.13.460054 — Posted: 2021-09-13
Rehabilitation in Survivors of COVID-19 (RE2SCUE): a nonrandomized, controlled, and open protocol
Campos, M. C., Nery, T., Alves, A. C. d. B., Speck, A. E., Vieira, D. S. R., Schneider, I. J. C., Matos, M. P. P., Arcencio, L., Aguiar, A. S.
10.1101/2021.09.06.21262986 — Posted: 2021-09-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).